Kidney Disease
161
113-128 of 145
- AHA 2019Invasive vs. conservative strategy does not reduce CV events in patients with CKD and ischemia
Sripal Bangalore, MD
- Expanding opportunities for SGLT2i in clinical cardiologyHeart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?
Prof. Faiez Zannad, MD
- Expanding opportunities for SGLT2i in clinical cardiologyHeart & Kidney interactions: What are the challenges for prevention and protection?
Prof. Christoph Wanner
Prof. John McMurray, MD
- Vascular calcification in kidney disease: Epigenetics as a novel approach?Epigenetic mechanisms targeting ALP: A pathway for prevention of vascular calcification?
Marta Ruiz-Ortega, PhD
- RAASi and Hyperkalaemia in Cardio Renal DiseaseRAAS inhibition in patients with kidney disease: Balancing the benefits and risks
Prof. Patrick Rossignol, MD
- SGLT2 inhibition in CKD: Discussing the key questions and evidenceOutcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?
Rajiv Agarwal, MD
- Vascular calcification in kidney disease: Epigenetics as a novel approach?Targeting residual cardiovascular risk & vascular calcification: The clinical perspective for BET inhibition
Vincent Brandenburg, MD
- Heart Failure, diabetes & SGLT2i: Time to change practice?The future of SGLT2i in HF: Managing patients without T2DM?
Prof. Adriaan Voors, MD
- Vascular calcification in kidney disease: Epigenetics as a novel approach?The role of ALP as predictor of CV events and vascular calcification in CKD
Dr. Mathias Haarhaus, MD
- SGLT2 inhibition in CKD: Discussing the key questions and evidenceThe clinical landscape of managing patients with CKD: Where are we now and what can we expect?
Will Herrington, MD
- SGLT2 inhibition in CKD: Discussing the key questions & evidenceThe known and unknown of SGLT2 inhibition in CKD
Carol Pollock, MD
- SGLT2 inhibition in CKD: Discussing the key questions & evidenceThe clinical landscape of managing patients with CKD
Prof. David Cherney
